SHP-623
- Generic Name
- SHP-623
Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 48
- Registration Number
- NCT02663687
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath